Presse, Media and Investor Relations
Only open exchange and dialogue can make change possible. We are always open for questions about us, medical cannabis, and the broad possibilities of phytopharmacological research.
Any questions related to regulatory affairs and all questions by regulatory authorities should be directed to firstname.lastname@example.org.
October 4 2019: btov and Single Family Office Invest in German Cannabis: 7 Million Euros for DEMECAN
May 27 2019: DEMECAN confirming award for German medical cannabis production
December 20 2018: DEMECAN Pharma Signs 10.000 kg Supply Agreement
DEMECAN Pharma has signed a supply agreement with the Canadian licensed medical cannabis producer Invictus MD of 10.000 kg cannabis flowers for the duration of 5 years. More information
can be found here.
Press about DEMECAN
May 20 2019: DEMECAN receives final approval to produce medical cannabis in Germany.
DEMECAN has been selected among 79 competitors by the German Bundesinstitut für Arzneimittel und Medizinprodukte BfArM (Federal Institute for Drugs and Medical Devices) as one of three companies to produce medical cannabis in Germany. In this competitive public tender that began July 2018, DEMECAN was awarded three of 13 possible lots, totaling at least 2400 kg over a period of 4 years. Selection criteria were mainly based on quality concepts for the production of cannabis that adhere to highest pharmaceutical standards. The cannabis produced by DEMECAN will be directly distributed to pharmacies by the German government.
Official BfArM press release (German)
For any press and media related questions, please contact email@example.com.
If you are interested in collaborations or investment opportunities into DEMECAN, write us at firstname.lastname@example.org.